Skip to main content
. 2022 Jun 9;21:125. doi: 10.1186/s12943-022-01603-y

Fig. 2.

Fig. 2

CBX2 silencing alters leukemic cell survival and induces cell death. A and B Proliferation assay with shCBX2#1, shCBX2#2, and shSCR in U937 (A) and K562 (B) cells; experiments were performed at 7 days of puromycin selection; error bars show SD of three biological replicates (*P < 0.05, **P ≤ 0.01). C and D CCK8 assay of CBX2 knock-down and shSCR-transduced U937 (C) and K562 (D) cells; experiments were performed at 7 days of puromycin selection; error bars show SD of three biological replicates (*P < 0.05, **P ≤ 0.01). E and F Percentage of PI-positive shCBX2- and shSCR-transduced U937 (E) and K562 (F) cells; experiments were performed at 7 days of puromycin selection; error bars show SD of three biological replicates (*P < 0.05, **P ≤ 0.01)